[Cardiotoxicity and immunomodulators: apropos of a case].
Bousquet
E
E
Amar
J
J
Payen
J L
JL
Salvador
M
M
Chamontin
B
B
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000139:chemically induced* / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000628:therapy*; D006801:Humans; D006973:Hypertension / Q000150:complications; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D008945:Mitral Valve Prolapse / Q000150:complications; D011063:Poly A-U / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011063:Poly A-U